Table 3.
Clinical features and diagnoses in patients with Lgi1 or Caspr2 antibodies
| Lgi1 (n = 55) | Caspr2 (n = 19) | Caspr2 versus Lgi1 (uncorrected P-values)* | |
|---|---|---|---|
| Male:female | 37 : 18 | 16 : 3 | NS |
| Amnesia | 47 | 10 | 0.002 |
| Confusion/disorientation | 41 | 8 | 0.009 |
| Seizures | 49 | 10 | 0.0004 |
| MRI medial temporal lobe high signal | 31 | 5 | 0.03 |
| Hyponatraemia | 34 | 2 | <0.0001 |
| Neuromyotonia | 2 | 10 | <0.0001 |
| Pain | 6 | 7 | 0.031 |
| Insomnia | 4 | 6 | 0.017 |
| Other sleep disorder | 12 | 0 | 0.028 |
| Any dysautonomia | 8 | 6 | NS |
| Active tumour (thymoma) | 0 | 6 (5) | 0.0002 |
| Weight loss | 2 | 6 | 0.003 |
| Death | 1 | 4 | 0.016 |
| Final diagnosis | |||
| Limbic encephalitis | 49 | 7 | <0.0001 |
| Morvan's syndrome | 2 | 3 | NS |
| Neuromyotonia only | 1 | 7 | 0.0002 |
| Epilepsy only | 1 | 2 | NS |
| Other | 2 | 0 | NS |
| Morvan’s syndrome or neuromyotonia | 3 | 10 | <0.0001 |
*The proportions of patients with each antibody who had particular clinical features were compared by Fishers’ exact test and have not been corrected for multiple comparisons. NS = not significant.